Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

This article was originally published in The Tan Sheet

Executive Summary

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

You may also be interested in...



FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation

A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. In news applauded by the device industry, the bill would also make available $85 million in previously sequestered FDA user fees.

New Food And Drug User Fees Face Long Odds In Congress

FDA’s $4.7 billion fiscal 2014 budget request proposes new fees including $58.9 million from food establishment registrations and inspections, $19.1 million from cosmetics firms and $15.04 million from medical product reinspections.

Generics Savings Once Again Could Help A Major US Health Care Reform Bill

A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel